CSL Behring Receives 2016 Marcum Innovator Breakthrough Award for Pioneering New Advancements in the Biotech/Healthcare Field

One of the world's top specialty biotherapeutics companies, CSL Behring continues to introduce innovations to address unmet medical needs or enhance current treatments.

News provided by

CSL Behring

Oct 27, 2016, 02:30 ET

KING OF PRUSSIA, Pa., Oct. 27, 2016 /PRNewswire/ -- Marcum LLP and Philadelphia SmartCEO magazine have recognized CSL Behring with the 2016 Innovator Breakthrough Award for developing novel products that save lives and improve quality of life for people with chronic and serious medical disorders.

In 2016 these included bringing to market two innovative recombinant factor therapies for treating hemophilia A and hemophilia B respectively. These two novel recombinant products aim to better protect patients from bleeds while reducing the treatment burden for patients and caregivers.

The Marcum awards recognize companies and individuals who add to the vitality and stability of the Philadelphia area. Dennis Jackman, CSL Behring's senior vice president of Global Healthcare Policy and External Affairs, expressed the company's ongoing commitment to the Philadelphia area, and said he is honoured to accept the award on behalf of CSL Behring and its more than 14,000 employees worldwide, including more than 500 in King of Prussia.

"Our innovative therapies begin with our dedicated team of R&D professionals worldwide," Jackman said. "We employ more than 1,100 R&D experts around the globe dedicated to discovering and developing new therapies that save and improve lives. Over the last five years we have invested $2.3 billion in R&D."

"The work of our research scientists is driven by our passion to make a difference in the lives of people with rare and chronic conditions. We will continue to unlock the potential of therapeutic proteins to save lives and protect the health of people living with chronic and serious conditions, as we have for the last 100 years."

About CSL Behring

CSL Behring is a global biotherapeutics leader, which is driven by its promise to save lives. Focused on serving patients' needs by using the latest technologies, we develop and deliver innovative therapies that are used to treat coagulation disorders, primary immune deficiencies, hereditary angioedema, inherited respiratory disease, and neurological disorders. The company's products are also used in cardiac surgery, organ transplantation, burn treatment and to prevent hemolytic disease of the newborn.

CSL Behring operates one of the world's largest plasma collection networks, CSL Plasma. The parent company, CSL Limited (ASX: CSL), headquartered in Melbourne, Australia, employs more than 16,000 people with operations in more than 30 countries. For more information visit www.cslbehring.com and follow us on www.Twitter.com/CSLBehring.

Media Contact
Name: Chris Florentz
Office: 610-878-4316; Mobile: 484-238-8509
Email: [email protected]

Logo - http://photos.prnewswire.com/prnh/20100914/PH63692LOGO

SOURCE CSL Behring